Alzheimer disease (AD) is the most common form of dementia. Pathologically, AD is
characterized by amyloid plaques and neurofibrillary tangles in the brain, with associated …

Converging evidence continues to point towards Tau aggregation and pathology formation
as central events in the pathogenesis of Alzheimer's disease and other Tauopathies …

A randomized, double-blind, placebo-controlled, 52-week study (no. NCT03068468)
evaluated gosuranemab, an anti-tau monoclonal antibody, in the treatment of progressive …

Frontotemporal lobar degeneration (FTLD) is one of the most common causes of early-onset
dementia and presents with early social–emotional–behavioural and/or language changes …

Abstract Glycogen synthase kinase-3 (GSK3) may be the busiest kinase in most cells, with
over 100 known substrates to deal with. How does GSK3 maintain control to selectively …

Progressive supranuclear palsy (PSP), previously believed to be a common cause of
atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes …

Background Progressive supranuclear palsy is a neurodegenerative disorder associated
with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds …

Abstract Nuclear Factor-Erythroid Factor 2 (Nrf2) is an important transcription factor that
regulates the expression of large number of genes in healthy and disease states. Nrf2 is …

Background: The ARGO study was a phase II, double-blind, placebo controlled, four parallel
arm trial of tideglusib in Alzheimer's disease (AD). Objective: To prove the clinical efficacy of …

Type 2 diabetes mellitus is characterized by the dysregulation of glucose homeostasis,
resulting in hyperglycaemia. Although current diabetes treatments have exhibited some …